Switching anti-TNF therapy in ankylosing spondylitis

Rheumatology

Volumn 47, Issue 11, 2008, Pages 1726-1727

  Pradeep, D John ^a   Keat, A C ^b   Gaffney, K ^a   Brooksby, A ^a   Leeder, J ^a   Harris, C ^b  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b NORTHWICK PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB;

ADULT; ANKYLOSING SPONDYLITIS; DISEASE DURATION; DISEASE SEVERITY; DIVERTICULITIS; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INJECTION SITE REACTION; LETTER; LEUKOPENIA; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT RESPONSE;

ADULT; ANTIRHEUMATIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 54449099689     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken334     Document Type: Letter

References (6)

1. Jois RN, Gaffney K, Keat A. Anti-tumour necrosis factor therapy for ankylosing spondylitis-unresolved issues. Rheumatology 2007;46:899-901.
2. Van der Heijde D, Dijkmans B, Geusens P et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis. Results of a randomized placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
3. Davis JCJr, Van der Heijde D, Braun J et al. Enbrel ankylosing spondylitis study group. Recombinant human tumour necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized controlled trial. Arthritis Rheum 2003; 48:3230-6.
4. Van der Heijde D, Kivitz A, Schiff MH et al. Efficacy and safety of adalimubab in patients with ankylosing spondylitis. Results of a multicenter, randomized, doubleblind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46.
5. Hyrich KL, Lunt M, Watson KD et al. Outcomes after switching from one-tumour necrosis factor alpha agent to a second anti-tumour necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20.
6. Coates LC, Cawkwell LS, Ng NWF et al. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology 2008;47:897-900.